Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - What's Next?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 413,080 shares changed hands during trading, a decline of 47% from the previous session's volume of 773,235 shares.The stock last traded at $15.54 and had previously closed at $14.96.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CAPR. Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. Maxim Group boosted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. HC Wainwright reissued a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday. Oppenheimer reaffirmed an "outperform" rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Stock Up 4.3 %

The stock has a market capitalization of $709.79 million, a price-to-earnings ratio of -14.73 and a beta of 3.98. The firm has a fifty day moving average of $16.70 and a 200-day moving average of $10.89.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp raised its position in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after acquiring an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $3,806,000. PFM Health Sciences LP acquired a new stake in Capricor Therapeutics during the 3rd quarter valued at $2,324,000. Renaissance Technologies LLC increased its position in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the second quarter worth $426,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.